Ovarian Cancer

© Getty Images

Positive pre-IND meeting with FDA for new ovarian cancer cell therapy

By Isabel Cameron

Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment...